According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
Other equities analysts also recently issued research reports about the company. Jefferies Group reissued a buy rating and set a $25.00 target price on shares of Atara Biotherapeutics in a research report on Tuesday, August 9th. JMP Securities reaffirmed a buy rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Canaccord Genuity reaffirmed a buy rating on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. Goldman Sachs Group Inc. downgraded Atara Biotherapeutics from a neutral rating to a sell rating and cut their price objective for the company from $23.00 to $16.00 in a research report on Thursday, September 15th. Finally, Citigroup Inc. upped their price objective on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a sell rating in a research report on Friday, August 19th. Three analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of Hold and a consensus price target of $26.14.
Shares of Atara Biotherapeutics (NASDAQ:ATRA) opened at 20.81 on Thursday. Atara Biotherapeutics has a 52 week low of $13.31 and a 52 week high of $40.80. The company has a 50-day moving average of $20.82 and a 200-day moving average of $20.14. The stock’s market capitalization is $599.56 million.
Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Monday, August 8th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. On average, analysts anticipate that Atara Biotherapeutics will post ($2.85) EPS for the current year.
In other news, CEO Isaac E. Ciechanover sold 9,600 shares of the stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $22.11, for a total transaction of $212,256.00. Following the transaction, the chief executive officer now owns 223,228 shares of the company’s stock, valued at approximately $4,935,571.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Isaac E. Ciechanover sold 7,200 shares of the stock in a transaction on Friday, September 16th. The stock was sold at an average price of $19.36, for a total value of $139,392.00. Following the transaction, the chief executive officer now directly owns 229,136 shares in the company, valued at approximately $4,436,072.96. The disclosure for this sale can be found here. Insiders own 16.10% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. BlackRock Group LTD increased its position in Atara Biotherapeutics by 76.8% in the first quarter. BlackRock Group LTD now owns 5,400 shares of the company’s stock worth $103,000 after buying an additional 2,345 shares during the last quarter. Barclays PLC boosted its stake in shares of Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares during the period. BlackRock Inc. boosted its stake in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares during the period. Finally, BlackRock Advisors LLC boosted its stake in shares of Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock worth $229,000 after buying an additional 2,361 shares during the period. 75.50% of the stock is currently owned by institutional investors and hedge funds.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.